Literature DB >> 15770697

Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice.

Eva-Pia Reich1, Long Cui, Lily Yang, Catherine Pugliese-Sivo, Andrei Golovko, Mary Petro, Galya Vassileva, Inhou Chu, Amin A Nomeir, Li-Kang Zhang, Xian Liang, Joseph A Kozlowski, Satwant K Narula, Paul J Zavodny, Chuan-Chu Chou.   

Abstract

The KCNN4 potassium-ion channel has been reported to play an important role in regulating antigen-induced T cell effector functions in vitro. This study presents the first evidence that a selective KCNN4 blocker, TRAM-34, confers protection against experimental autoimmune encephalomyelitis (EAE) in the mouse model. Treatment with the KCNN4 blocker did not prevent infiltration of T cells in the spinal cord, but resulted in the reduction of both the protein and the message levels of TNF-alpha and IFN-gamma as well as the message levels of several other pro-inflammatory molecules in the spinal cord. Plasma concentrations of TRAM-34 within a 24-h period were between the in vitro IC(50) and IC(90) values for the KCNN4 channel. The effect of TRAM-34 was reversible, as indicated by the development of clinical EAE symptoms within 48 h after withdrawal of treatment. In summary, our data support the idea that KCNN4 channels play a critical role in the immune response during the development of MOG-induced EAE in C57BL/6 mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770697     DOI: 10.1002/eji.200425954

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

1.  Targeting ion channels for the treatment of autoimmune neuroinflammation.

Authors:  Stefan Bittner; Sven G Meuth
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells.

Authors:  Shekhar Srivastava; Kyung Ko; Papiya Choudhury; Zhai Li; Amanda K Johnson; Vivek Nadkarni; Derya Unutmaz; William A Coetzee; Edward Y Skolnik
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

3.  The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke.

Authors:  Yi-Je Chen; Girija Raman; Silke Bodendiek; Martha E O'Donnell; Heike Wulff
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-13       Impact factor: 6.200

4.  Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity.

Authors:  Izumi Maezawa; Pavel I Zimin; Heike Wulff; Lee-Way Jin
Journal:  J Biol Chem       Date:  2010-10-22       Impact factor: 5.157

Review 5.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

6.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

7.  Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.

Authors:  David Paul Jenkins; Weifeng Yu; Brandon M Brown; Lars Damgaard Løjkner; Heike Wulff
Journal:  Assay Drug Dev Technol       Date:  2013 Nov-Dec       Impact factor: 1.738

Review 8.  Potassium channel expression and function in microglia: Plasticity and possible species variations.

Authors:  Hai M Nguyen; Linda V Blomster; Palle Christophersen; Heike Wulff
Journal:  Channels (Austin)       Date:  2017-03-01       Impact factor: 2.581

9.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

Review 10.  The CNS under pathophysiologic attack--examining the role of K₂p channels.

Authors:  Petra Ehling; Manuela Cerina; Thomas Budde; Sven G Meuth; Stefan Bittner
Journal:  Pflugers Arch       Date:  2014-12-09       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.